Control study of mirtazapine and fluoxetine in therapy of depression

Chinese Journal of Clinical Rehabilitation

Volumn 7, Issue 30, 2003, Pages 4102-4104

  Zhang, Ji Shui ^a   Liu, Tie Qiao ^a   Zhao, Jing Ping ^a   Hao, Wei ^a   Xie, Guang Rong ^a   Su, Lin Yan ^a   Yue, Wei Hua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; MIRTAZAPINE; NEW DRUG;

AGITATION; ANXIETY DISORDER; ARTICLE; CHINESE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; EXCITATION; HAMILTON SCALE; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MENTAL DISEASE; RATING SCALE; RELIABILITY; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 2442565683     PISSN: 16715926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Frazer A. Pharmacology of Antidepressants. J Clin Psychopharmacol 1997; 17 (2s): 2-18
2. Wang LH, Yang GS, Guo TR. Remeron. Zhongguo Xinyao Zazhi 2002; 11(4): 328-9
3. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995; 56: 519-25
4. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990; 26: 191-6
5. Boer DT, Nefkens F, Helvorit VA. The α2-adrenoceptorant agonist Org3770 enhances serotonin transmission in vivo. Eur J Pharmacology 1994; 253: R5-R63
6. Boer DT. The effects of mirtazapine on centralnoradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995; 10(suppl 4): 219-34
7. Haddjeri N, Blier P, Demontigny C. Noradrenergic Modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmcol 1995; 10 (suppl 4); 11-7
8. Johnson AM. Selective serotonin re-uptake inhibitors: The clinical use of citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. In Feighner JP, Boyer WE (Eds.), Perspectives in psychiatry. Chichester, England: Wiley 1991: 37-70
9. Greenberg R, Bornstein R, Zborowski M, et al. A meta-analysis of fluoxetine in the treatment of depression. J Nerv Ment Dis 1994; 182: 547-51
10. Chen XG, Zhao JP, Li LH, et al. A controlled clinical trials of remeron and fluoxetine in depressive patients. Zhongguo Linchuang Kangfu 2002; 6(15): 2300
11. Wheatly DP, Van Moffaertm, Timmermanl, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine inpatients with moderate to sever major depressive disorder. J Clin Psychiatry 1998; 59: 306-12
12. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord 1998; 51: 267-85